• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.家族性肺纤维化:遗传特征与临床意义。
Chest. 2021 Nov;160(5):1764-1773. doi: 10.1016/j.chest.2021.06.037. Epub 2021 Jun 26.
2
A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features.新斯科舍省家族性和散发性特发性肺纤维化患者队列:临床和遗传特征。
Respir Res. 2012 Aug 1;13(1):64. doi: 10.1186/1465-9921-13-64.
3
The Genetic Landscape of Familial Pulmonary Fibrosis.家族性肺纤维化的遗传学特征
Am J Respir Crit Care Med. 2023 May 15;207(10):1345-1357. doi: 10.1164/rccm.202204-0781OC.
4
The genetic basis of idiopathic pulmonary fibrosis.特发性肺纤维化的遗传基础。
Eur Respir J. 2015 Jun;45(6):1717-27. doi: 10.1183/09031936.00163814. Epub 2015 Apr 2.
5
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.重测序研究证实,宿主防御和细胞衰老基因变异可导致特发性肺纤维化的发生风险增加。
Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.
6
Pulmonary fibrosis in the era of stratified medicine.分层医学时代的肺纤维化
Thorax. 2016 Dec;71(12):1154-1160. doi: 10.1136/thoraxjnl-2016-209172. Epub 2016 Oct 31.
7
Idiopathic pulmonary fibrosis: update on genetic discoveries.特发性肺纤维化:遗传发现的最新进展。
Proc Am Thorac Soc. 2011 May;8(2):158-62. doi: 10.1513/pats.201008-056MS.
8
An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.一项评估罕见基因变异在肺纤维化中作用的外显子组测序研究。
Am J Respir Crit Care Med. 2017 Jul 1;196(1):82-93. doi: 10.1164/rccm.201610-2088OC.
9
The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis.端粒与表面活性剂相关的家族性肺纤维化患者肺部炎症细胞浸润和纤维化的程度
Front Med (Lausanne). 2021 Sep 24;8:736485. doi: 10.3389/fmed.2021.736485. eCollection 2021.
10
Recent advances in the genetics of idiopathic pulmonary fibrosis.特发性肺纤维化的遗传学研究进展。
Curr Opin Pulm Med. 2023 Sep 1;29(5):399-405. doi: 10.1097/MCP.0000000000000989. Epub 2023 Jul 6.

引用本文的文献

1
DNA damage response and cell fate decisions across the lifespan: from fetal development to age-related respiratory diseases.整个生命周期中的DNA损伤反应与细胞命运决定:从胎儿发育到与年龄相关的呼吸系统疾病
Cell Biosci. 2025 Aug 2;15(1):114. doi: 10.1186/s13578-025-01442-6.
2
Endothelin receptor antagonists target EDNRB and modulate the progression of idiopathic pulmonary fibrosis via anoikis-related genes.内皮素受体拮抗剂作用于内皮素受体B(EDNRB),并通过失巢凋亡相关基因调节特发性肺纤维化的进展。
Front Med (Lausanne). 2025 Jun 16;12:1593376. doi: 10.3389/fmed.2025.1593376. eCollection 2025.
3
Polygenic Risk and Rare Variants in Endotypes of Idiopathic Pulmonary Fibrosis.特发性肺纤维化内型中的多基因风险与罕见变异
medRxiv. 2025 Jun 4:2025.05.22.25328177. doi: 10.1101/2025.05.22.25328177.
4
Updates in Diagnostic Tools for ILD.间质性肺疾病诊断工具的更新
J Clin Med. 2025 Apr 24;14(9):2924. doi: 10.3390/jcm14092924.
5
Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review.端粒相关形式的进行性纤维化间质性肺病(肺纤维化)患者肺移植的结果:一项系统评价。
JHLT Open. 2024 Jan 17;3:100054. doi: 10.1016/j.jhlto.2024.100054. eCollection 2024 Feb.
6
Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis.多学科团队讨论对遗传性肺纤维化的影响。
Respirology. 2025 Jun;30(6):523-532. doi: 10.1111/resp.70039. Epub 2025 Mar 26.
7
Deciphering the cellular and molecular landscape of pulmonary fibrosis through single-cell sequencing and machine learning.通过单细胞测序和机器学习解析肺纤维化的细胞和分子图谱。
J Transl Med. 2025 Jan 2;23(1):3. doi: 10.1186/s12967-024-06031-8.
8
Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases.纤维化间质性肺疾病家族史的诊断和预后意义
Respir Res. 2024 Dec 18;25(1):433. doi: 10.1186/s12931-024-03063-y.
9
The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey.不同医疗环境下家族性肺纤维化的管理:我们该何去何从?一项意大利全国性调查。
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Sep 24;41(3):e2024047. doi: 10.36141/svdld.v41i3.15744.
10
Clinical Impact of Telomere Length Testing for Interstitial Lung Disease.端粒长度检测对间质性肺疾病的临床影响。
Chest. 2024 Nov;166(5):1071-1081. doi: 10.1016/j.chest.2024.06.006. Epub 2024 Jun 29.

本文引用的文献

1
Genetic disorders of the surfactant system: focus on adult disease.表面活性物质系统的遗传性疾病:重点关注成人疾病。
Eur Respir Rev. 2021 Feb 16;30(159). doi: 10.1183/16000617.0085-2020. Print 2021 Mar 31.
2
Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease.Hermansky-Pudlak 综合征肺纤维化:一种罕见的遗传性间质性肺疾病。
Eur Respir Rev. 2021 Feb 2;30(159). doi: 10.1183/16000617.0193-2020. Print 2021 Mar 31.
3
Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease.特发性肺纤维化家族史预示着特发性间质性肺病患者的生存预后更差。
Chest. 2021 May;159(5):1913-1921. doi: 10.1016/j.chest.2021.01.026. Epub 2021 Jan 21.
4
Psychological impact of genetic and clinical screening for pulmonary fibrosis on asymptomatic first-degree relatives of affected individuals.遗传性和临床性肺纤维化筛查对无症状肺纤维化患者一级亲属的心理影响。
Thorax. 2021 Jun;76(6):621-623. doi: 10.1136/thoraxjnl-2020-216244. Epub 2021 Jan 22.
5
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation.吡非尼酮和尼达尼布在患有特发性肺纤维化且携带端粒相关基因突变患者中的安全性和有效性。
Eur Respir J. 2021 Feb 11;57(2). doi: 10.1183/13993003.03198-2020. Print 2021 Feb.
6
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study.端粒长度与特发性肺纤维化和慢性阻塞性肺疾病风险:一项孟德尔随机研究。
Lancet Respir Med. 2021 Mar;9(3):285-294. doi: 10.1016/S2213-2600(20)30364-7. Epub 2020 Nov 13.
7
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis.慢性过敏性肺炎中的白细胞端粒长度与霉酚酸酯治疗
Eur Respir J. 2021 Mar 4;57(3). doi: 10.1183/13993003.02872-2020. Print 2021 Mar.
8
Spectrum of Fibrotic Lung Diseases.纤维化性肺疾病谱
N Engl J Med. 2020 Sep 3;383(10):958-968. doi: 10.1056/NEJMra2005230.
9
Familial hypersensitivity pneumonitis triggered by exposure during carpooling.拼车过程中接触引发的家族性过敏性肺炎。
ERJ Open Res. 2020 Aug 17;6(3). doi: 10.1183/23120541.00233-2020. eCollection 2020 Jul.
10
Telomere length in patients with unclassifiable interstitial lung disease: a cohort study.无法分类的间质性肺疾病患者的端粒长度:一项队列研究。
Eur Respir J. 2020 Aug 27;56(2). doi: 10.1183/13993003.00268-2020. Print 2020 Aug.

家族性肺纤维化:遗传特征与临床意义。

Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

机构信息

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

出版信息

Chest. 2021 Nov;160(5):1764-1773. doi: 10.1016/j.chest.2021.06.037. Epub 2021 Jun 26.

DOI:10.1016/j.chest.2021.06.037
PMID:34186035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8628177/
Abstract

Pulmonary fibrosis comprises a wide range of fibrotic lung diseases with unknown pathogenesis and poor prognosis. Familial pulmonary fibrosis (FPF) represents a unique subgroup of patients in which at least one other relative is also affected. Patients with FPF exhibit a wide range of pulmonary fibrosis phenotypes, although idiopathic pulmonary fibrosis is the most common subtype. Despite variable disease manifestations, patients with FPF experience worse survival compared with their counterparts with the sporadic disease form. Therefore, ascertaining a positive family history not only provides prognostic value but should also raise suspicion for the inheritance of an underlying causative genetic variant within kindreds. By focusing on FPF kindreds, rare variants within surfactant metabolism and telomere maintenance genes have been discovered. However, such genetic variation is not solely restricted to FPF, as similar rare variants are found in patients with seemingly sporadic pulmonary fibrosis, further supporting the idea of genetic susceptibility underlying pulmonary fibrosis as a whole. Researchers are beginning to show how the presence of rare variants may inform clinical management, such as informing predisposition risk for yet unaffected relatives as well as informing prognosis and therapeutic strategy for those already affected. Despite these advances, rare variants in surfactant and telomere-related genes only explain the genetic basis in about one-quarter of FPF kindreds. Therefore, research is needed to identify the missing genetic contributors of pulmonary fibrosis, which would not only improve our understanding of disease pathobiology but may offer additional opportunities to improve the health of patients.

摘要

肺纤维化是一组广泛的纤维化肺部疾病,其发病机制未知,预后不良。家族性肺纤维化(FPF)是一组独特的患者亚群,至少有一位其他亲属也受到影响。FPF 患者表现出广泛的肺纤维化表型,尽管特发性肺纤维化是最常见的亚型。尽管疾病表现存在差异,但与散发性疾病形式的患者相比,FPF 患者的生存率更差。因此,确定阳性家族史不仅提供预后价值,还应引起对家族中潜在致病遗传变异的遗传怀疑。通过关注 FPF 家族,已经发现了表面活性剂代谢和端粒维持基因中的罕见变异。然而,这种遗传变异不仅限于 FPF,因为在看似散发性肺纤维化的患者中也发现了类似的罕见变异,这进一步支持了整个肺纤维化存在遗传易感性的观点。研究人员开始展示罕见变异如何为临床管理提供信息,例如告知尚未受影响的亲属的易感性风险,以及为已经受影响的亲属提供预后和治疗策略。尽管取得了这些进展,但表面活性剂和端粒相关基因中的罕见变异仅能解释大约四分之一的 FPF 家族的遗传基础。因此,需要研究以确定肺纤维化缺失的遗传贡献者,这不仅将提高我们对疾病发病机制的理解,而且可能为改善患者健康提供额外的机会。